54 unknown, 16 completed, 4 not yet recruiting, 4 recruiting. 47 Phase 2, 15 Phase 3, 11 Phase 4, 5 Phase 1, 2 Not applicable.
Follow icotinib: new trials by email Literature Review of icotinib trials Research Report on icotinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study Comparing the Efficacy and Safety of Befotertinib Versus Icotinib in Patients With Previously Untreated EGFR-sensitive Mutation-positive Non-small Cell Lung Cancer With ECOG Score ≥2 Befotertinib, Icotinib - Locally Advanced or Metastatic Non-small Cell Lung Cancer With Previously Untreated EGFR-sensitive Mutations and ECOG Performance Status Score ≥2 | Phase 4 | Not yet recruiting | Zhou Chengzhi | 100 | 2026-11-30 | 2026-10-28 |
| Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung Cancer Icotinib, Routine Observational - NSCLC (Non-small Cell Lung Cancer) | Recruiting | Betta Pharmaceuticals Co., Ltd. | 2572 | 2026-09-01 | 2026-09-08 | |
| Therapy for Advanced NSCLC With EGFR 19delins Mutation Icotinib/Gefitinib - Lung Cancer | Early Phase 1 | Not yet recruiting | Fuzhou General Hospital | 94 | 2026-03-30 | 2026-03-09 |
| Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations Icotinib, Rezivertinib, Ensartinib - Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | The First Affiliated Hospital of Guangzhou Medical University | 270 | 2025-05-01 | 2025-05-06 |
| Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations Icotinib, Befotertinib - Non-small Cell Lung Cancer Metastatic, EGFR G719X | Phase 2 | Recruiting | Sun Yat-sen University | 23 | 2024-07-17 | 2024-07-25 |
| Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations Befotertinib + Icotinib placebo, Icotinib + Befotertinib placebo - Non-Small Cell Lung Cancer, EGFR Sensitive Mutation | Phase 3 | Recruiting | Betta Pharmaceuticals Co., Ltd. | 570 | 2023-03-28 | 2023-09-22 |
| A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection Icotinib - Non-Small Cell Lung Cancer | Phase 2 | Unknown | Wu Nan | 90 | 2022-09-01 | 2022-08-24 |
| Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation Bevacizumab, Icotinib - Carcinoma, Non-Small-Cell Lung, Bevacizumab | Phase 2 | Completed | Tianjin Medical University Cancer Institute and Hospital | 35 | 2022-01-30 | 2026-02-24 |
| Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma Icotinib, Cisplatin, Carboplatin - NSCLC, EGF-R Positive Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Liaoning Cancer Hospital & Institute | 45 | 2022-01-01 | 2021-12-10 |
| A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer Icotinib, Cisplatin, Carboplatin - Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Peking University Cancer Hospital & Institute | 27 | 2021-10-25 | 2021-11-03 |
| Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer Icotinib, Befotertinib - Non-Small Cell Lung Cancer | Phase 2 | Unknown | Betta Pharmaceuticals Co., Ltd. | 30 | 2021-08-12 | 2024-08-23 |
| Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC Anlotinib, Icotinib - Non Small Cell Lung Cancer | Phase 3 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 206 | 2021-03-12 | 2021-03-15 |
| Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study Bevacizumab, Erlotinib, Gefitinib - NSCLC | Unknown | Guangdong Association of Clinical Trials | 272 | 2020-10-07 | 2020-10-20 | |
| Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations. Icotinib - Non-squamous Non-small Cell Lung Cancer | Phase 3 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 70 | 2019-07-01 | 2019-06-20 |
| Adjuvant Chemotherapy With or Without Intercalated Icotinib Icotinib, Placebo, chemotherapy - Carcinoma, Non-Small-Cell Lung | Not applicable | Unknown | Nanfang Hospital, Southern Medical University | 174 | 2019-07-01 | 2019-06-12 |
| Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer Anlotinib Hydrochloride, Gefitinib, Icotinib - Non-Small-Cell Lung | Not applicable | Unknown | The First Affiliated Hospital of Soochow University | 66 | 2019-03-30 | 2019-01-30 |
| Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC Anlotinib Plus Icotinib - Non Small Cell Lung Cancer | Phase 2 | Completed | Tianjin Medical University Cancer Institute and Hospital | 60 | 2018-12-01 | 2021-03-15 |
| Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer Icotinib - EGF-R Positive Non-Small Cell Lung Cancer | Phase 2 | Unknown | Betta Pharmaceuticals Co., Ltd. | 36 | 2018-12-01 | 2018-11-21 |
| Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation Icotinib, WBRT or SRS - Non-Small Cell Lung Cancer, Brain Metastases | Phase 2 | Unknown | Betta Pharmaceuticals Co., Ltd. | 162 | 2018-12-01 | 2018-11-27 |
| Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer Icotinib - EGF-R Positive Non-Small Cell Lung Cancer | Phase 2 | Unknown | Betta Pharmaceuticals Co., Ltd. | 60 | 2018-10-01 | 2018-07-18 |
Showing 20 of 81. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (45) · Lung Neoplasms (9) · Brain Neoplasms (7) · Adenocarcinoma (2) · Adenocarcinoma of Lung (2) · Esophageal Neoplasms (2) · Nasopharyngeal Carcinoma (2) · Neoplasms (2) · Pancreatic Neoplasms (2) · Breast Neoplasms (1) · Bronchial Neoplasms (1) · Drug-Related Side Effects and Adverse Reactions (1) · Neoplasm Metastasis (1) · Neoplasms, Second Primary (1) · Neurofibromatosis 2 (1)
Betta Pharmaceuticals Co., Ltd. (35) · Sun Yat-sen University (5) · Tianjin Medical University Cancer Institute and Hospital (4) · Nanfang Hospital, Southern Medical University (3) · Chinese Academy of Medical Sciences (2) · Guangdong Association of Clinical Trials (2) · Zhejiang Cancer Hospital (2) · Zhejiang University (2) · Anhui Medical University (1) · Beijing Haidian Hospital (1) · China Medical University, China (1) · Chinese PLA General Hospital (1) · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (1) · First People's Hospital of Hangzhou (1) · Fuda Cancer Hospital, Guangzhou (1)
China (68)
Kaican Cai, MD (2) · Shixiu Wu, MD (2) · Shugeng Gao (2) · Si-Yu Wang, MD (2) · Weimin Mao, MD (2) · Yan Sun, MD (2) · Zhang Yi Ping, M.D. (2) · BingQiang Ni, MD (1) · Caicun Zhou, MD (1) · ChangJie Huang, MD (1) · Chao Zhou, MD. (1) · Chen Ming (1) · Dingzhi Huang, Doctor (1) · Feng Ye, MD (1) · Fenlai Tan, M.D./Ph.D. (1)
PMID 23948351, PMID 22112293, PMID 22967997, PMID 25175099, PMID 26148750, PMID 26474174, PMID 26599904, PMID 26762738, PMID 26980473, PMID 27619516, PMID 28734822, PMID 28945850, PMID 31200823, PMID 32606956, PMID 33026449, PMID 34280355, PMID 35862035, PMID 36816343, PMID 37348348, PMID 37543587, PMID 40421698, PMID 40866342, PMID 42660909